diltiazem has been researched along with Acid beta-Glucosidase Deficiency in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahuran, D; Rigat, B | 1 |
| Grabowski, GA; Liou, B; Quinn, B; Ran, H; Sun, Y; Xu, YH | 1 |
| Kelly, JW; Mu, TW; Ong, DS; Palmer, AE | 1 |
3 other study(ies) available for diltiazem and Acid beta-Glucosidase Deficiency
| Article | Year |
|---|---|
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
Topics: Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Diltiazem; Dose-Response Relationship, Drug; Enzyme Activation; Fibroblasts; Gaucher Disease; Glucosylceramidase; Hot Temperature; Humans; Hydrogen-Ion Concentration; Imino Pyranoses; Lysosomes; Phenotype; Verapamil | 2009 |
In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Diltiazem; Disease Models, Animal; Fibroblasts; Gaucher Disease; Glucosylceramidase; Homozygote; Mice; Mice, Transgenic; Models, Biological; Mutation; Skin; Verapamil | 2009 |
Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis.
Topics: Amino Acid Substitution; Calcium; Calcium Channel Blockers; Diltiazem; Endoplasmic Reticulum; Gaucher Disease; Glucosylceramidase; Humans; Lysosomes; Protein Folding; Protein Processing, Post-Translational; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Vasodilator Agents; Verapamil | 2010 |